Summary: Neurostimulation implants used to treat drug-resistant epilepsy also help to reduce mental health symptoms in patients.
Source: University of Alabama at Birmingham
People with drug-resistant epilepsy also can have deleterious neuropsychiatric symptoms like anxiety, depression, psychosis and impaired memory. These have negative impacts on quality of life, and there is an unmet need to improve therapy for such patients. Diagnosing and monitoring such neurobehavioral symptoms is challenging because their presentation can overlap with seizures.
Sandipan Pati, M.D., and colleagues at the University of Alabama at Birmingham now report cases of five patients who found better treatments for those symptoms using data collected — while the patients were at home — from implanted neurostimulators placed in their brains to control their epileptic seizures. This is an extra benefit from the implanted Responsive Neurostimulator Systems, due to the system’s ability to record brain electrocorticography data initiated when a patient senses an anxiety or panic attack.
This data is key to showing whether the neuropsychiatric comorbidity began before, during or after an epileptic seizure. This guides medication or therapy changes that can reduce the negative symptoms caused by attacks that initiate outside of seizures, including psychogenic nonepileptic seizures. The only other way to get this useful information is video-electroencephalography in an inpatient clinic, with stays that typically last three to five days.
“Treating these patients can be challenging, and one reason for this is that sometime seizures can mimic anxiety and panic attacks, or psychosis,” Pati said. “Seizure-induced anxiety or psychosis is treated with anti-seizure medications, while ‘pure’ psychosis is treated with anti-psychotic medications. This study will be attractive for patients, as anxiety or depression is a common problem in epilepsy, and patients get frustrated as they think we are always focused on treating seizures and not depression.”
Pati, an associate professor in the UAB Department of Neurology, leads an epilepsy neuromodulation clinic at UAB to improve seizure control for drug-resistant epilepsy.
When a patient feels onset of a neuropsychiatric incident, he or she can use a magnet to initiate brain recording, with the prior minute of signals retained. They then can transfer the data to a password-protected laptop, and physicians can review the data to guide therapies.
Among 21 patients with implanted neurostimulators studied by Pati and colleagues, there were five patients with significant neurobehavioral comorbidities whose presentation overlapped with their seizures and, hence, could benefit from the use of the electrocorticography data stored by the neurostimulators. All saw improvements from changes in drug treatment, cognitive behavioral therapy or counseling to reduce symptoms such as panic-like attacks, psychosis and psychogenic nonepileptic seizures.
“The availability of ambulatory electrocorticography provides the opportunity to manage comorbidities in epilepsy that can mimic seizures and contribute to the overall poor quality of life,” Pati said.
Source:
University of Alabama at Birmingham
Media Contacts:
Jeffrey B Hansen – University of Alabama at Birmingham
Image Source:
The image is in the public domain.
Original Research: Closed access
“Optimizing therapies for neurobehavioral comorbidities of epilepsy using chronic ambulatory electrocorticography”. Sandipan Pati et al.
Epilepsy & Behavior doi:10.1016/j.yebeh.2019.106814.
Abstract
Optimizing therapies for neurobehavioral comorbidities of epilepsy using chronic ambulatory electrocorticography
There is an unmet need to improve therapy for neuropsychiatric comorbidities that are highly prevalent in persons with epilepsy (PWE). However, diagnosing and monitoring the neurobehavioral symptoms is challenging as their presentation can overlap with seizures. In this retrospective study, we report the advantage of chronic ambulatory electrocorticography (ECoG) from implanted Responsive Neurostimulator System (RNS®) in characterizing these psychosomatic paroxysms as a possible ictal, postictal, or interictal phenomenon and how the diagnosis guided the therapy choices. Five out of 21 patients with RNS had neuropsychiatric symptoms (panic attack, psychosis, conversion, and somatization disorders) that overlapped with their seizure semiology and were found to benefit from the use of RNS ECoG data by timely diagnosing and titrating targeted therapies. The cases illustrate the use of RNS ECoG data in diagnosing and improving the management of comorbidities in PWE. The ability to access RNS ECoG data and correlate it with patient symptoms is unique among available therapeutic options for PWE.
